Streetbeat News

ALMS

Alumis Inc.

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

5.13

Mkt cap

281M

Volume

458K

High

5.59

P/E Ratio

-1.18

52-wk high

13.53

Low

5.12

Div yield

N/A

52-wk low

4.74

Halper Sadeh LLC is investigating the fairness of the merger between Alumis Inc. and ACELYRIN, INC. for Alumis shareholders. Post-merger, Alumis shareholders will own 55% of the combined entity.

Portfolio Pulse from

February 07, 2025 | 3:00 am

Alumis and ACELYRIN are merging to form a late-stage clinical biopharma company focused on developing and commercializing therapies for immune-mediated diseases.

Portfolio Pulse from

February 06, 2025 | 9:30 pm

Alumis Inc. reported its Q3 2024 financial results, highlighting progress in its clinical programs, including Phase 3 trials for ESK-001 in plaque psoriasis and Phase 2b trials for systemic lupus erythematosus.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

Top Wall Street analysts initiated coverage on several companies, including Alumis Inc., Enliven Therapeutics, Intensity Therapeutics, Terns Pharmaceuticals, and Braze. Notably, Alumis received an Outperform rating with a $25 price target, while Braze was rated Neutral with a $30 target.

Portfolio Pulse from Avi Kapoor

October 31, 2024 | 3:37 pm

Baird analyst Brian Skorney has initiated coverage on Alumis (NASDAQ:ALMS) with an Outperform rating and set a price target of $25.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 9:57 am

HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS) with a Buy rating and a $30 price target, citing its lead drug candidate ESK-001's superior profile over Bristol Myers' Sotyktu. ESK-001 is in Phase 3 trials for psoriasis and Phase 2 for lupus, with potential peak sales of $1.9 billion and $2.0 billion, respectively.

Portfolio Pulse from Vandana Singh

October 17, 2024 | 6:32 pm

Several Wall Street analysts initiated coverage on various stocks with new ratings and price targets. Notably, Gilead Sciences received an Outperform rating with a $105 price target, while Grocery Outlet, First Watch Restaurant Group, InMode, and Alumis also received new ratings.

Portfolio Pulse from Avi Kapoor

October 17, 2024 | 1:05 pm

Alumis shares rose following HC Wainwright & Co.'s initiation of coverage with a Buy rating and a $30 price target.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:39 pm

HC Wainwright & Co. has initiated coverage on Alumis (NASDAQ:ALMS) with a Buy rating and set a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 10:53 am

Jim Cramer expressed his interest in buying Target Corporation (TGT) and Merck (MRK) stocks, while dismissing SoundHound AI (SOUN) as a 'meme stock'. Target recently appointed Jim Lee from PepsiCo as its CFO. Unity Software (U) received an Underperform rating from Macquarie, and Alumis (ALMS) is considered highly speculative by Cramer.

Portfolio Pulse from Avi Kapoor

October 09, 2024 | 12:36 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.